Skip to content
TriangleGet started
← Full study record

NCT03654833 · FLOW

Participant flow

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma · Source last updated 2026-08-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Rucaparib in DNA damage sensitive relapsed mesothelioma. 600mg twice daily (BID) every 28 days. Tablet. Oral use.
    id
    FG000
    title
    MiST-1
  2. description
    Abemaciclib in p16INK4A negative mesothelioma. 200mg twice daily (BID) for 28 days. Capsule. Oral use.
    id
    FG001
    title
    MiST-2
  3. description
    Pembrolizumab and bemcentinib in relapsed mesothelioma. Bemcentinib will be administered once daily. On first 3 days of administration the dose will be a loading of 400mg. From Day 4 onwards, patients will receive a daily dose of 200mg. Each cycle will be 21 days. Pembrolizumab will be given at a fixed dose of 200mg via IV infusion on Day 1 of each 21-day cycle. Each drug will be administered for up to 35 cycles or until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression. Injection, Capsule. Intravenous use, Oral use.
    id
    FG002
    title
    MiST-3
  4. description
    Atezolizumab and Bevacizumab in relapsed mesothelioma. Atezolizumab will be given as a fixed dose of 1200mg via IV infusion on day 1 of a 21-day cycle. Bevacizumab will be given as 15 mg/kg via IV infusion on Days 1 of a 21-day cycle. Infusion. Intravenous use.
    id
    FG003
    title
    MiST-4
  5. description
    Dostarlimab and Niraparib in Patients with Platinum Sensitive Relapsed Mesothelioma. Niraparib will be administered once daily depending on patient's weight and platelet count. A cycle consist of 21 days and there will be up to 35 cycles in total: • ≥77 kg and ≥150,000 μL 300 mg (3 X 100 mg capsules) • \<77 kg or \<150,000 μL 200 mg (2 X 100 mg capsules) Dostarlimab will be given at a fixed dose of 500mg via IV infusion on Day 1 of each 21-day cycle for 4 cycles. Followed by 1000mg via IV infusion on Day 1 of each 42-day cycle for up to 24 months. • Each will be administered for up to 24 months or until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression. Capsule, Infusion. Oral use, Intravenous use.
    id
    FG004
    title
    MiST-5
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      2. group Id
        FG001
        num Subjects
        26
      3. group Id
        FG002
        num Subjects
        26
      4. group Id
        FG003
        num Subjects
        26
      5. group Id
        FG004
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        26
      2. group Id
        FG001
        num Subjects
        26
      3. group Id
        FG002
        num Subjects
        26
      4. group Id
        FG003
        num Subjects
        26
      5. group Id
        FG004
        num Subjects
        26
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Baseline
  2. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Physician Decision
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        3
      5. group Id
        FG004
        num Subjects
        0
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        6
      3. group Id
        FG002
        num Subjects
        4
      4. group Id
        FG003
        num Subjects
        5
      5. group Id
        FG004
        num Subjects
        5
      type
      Lack of Efficacy
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Toxicity
    5. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Patient Choice
    6. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Did not attend 12 week CT scan
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      2. group Id
        FG001
        num Subjects
        26
      3. group Id
        FG002
        num Subjects
        26
      4. group Id
        FG003
        num Subjects
        26
      5. group Id
        FG004
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        18
      2. group Id
        FG001
        num Subjects
        14
      3. group Id
        FG002
        num Subjects
        18
      4. group Id
        FG003
        num Subjects
        18
      5. group Id
        FG004
        num Subjects
        21
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        12
      3. group Id
        FG002
        num Subjects
        8
      4. group Id
        FG003
        num Subjects
        8
      5. group Id
        FG004
        num Subjects
        5
      type
      NOT COMPLETED
    title
    12 Weeks
  3. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        1
      type
      Physician Decision
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Missed 24 week visit
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        4
      4. group Id
        FG003
        num Subjects
        1
      5. group Id
        FG004
        num Subjects
        3
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Patient Choice
    5. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        4
      4. group Id
        FG003
        num Subjects
        8
      5. group Id
        FG004
        num Subjects
        6
      type
      Lack of Efficacy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        18
      2. group Id
        FG001
        num Subjects
        14
      3. group Id
        FG002
        num Subjects
        18
      4. group Id
        FG003
        num Subjects
        18
      5. group Id
        FG004
        num Subjects
        21
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        10
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        10
      4. group Id
        FG003
        num Subjects
        9
      5. group Id
        FG004
        num Subjects
        11
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        8
      4. group Id
        FG003
        num Subjects
        9
      5. group Id
        FG004
        num Subjects
        10
      type
      NOT COMPLETED
    title
    24 Weeks
pre Assignment Details
The MiST Master protocol states "Trial Design of the MiST study is in three stages: Stage 1-molecular pre-screening: The MiST Master protocol describes the identification of patients, biomarker testing and analysis. Stage 2- Treatment: The MiST treatment protocol will be specific to the treatment allocated to the patient Stage 3-Genomic Profiling": The Screening target for the pre-screening stage was 186 patients. After screening the number recruited for the treatment stage was 130 patients.
Complete source fields
groups
  1. description
    Rucaparib in DNA damage sensitive relapsed mesothelioma. 600mg twice daily (BID) every 28 days. Tablet. Oral use.
    id
    FG000
    title
    MiST-1
  2. description
    Abemaciclib in p16INK4A negative mesothelioma. 200mg twice daily (BID) for 28 days. Capsule. Oral use.
    id
    FG001
    title
    MiST-2
  3. description
    Pembrolizumab and bemcentinib in relapsed mesothelioma. Bemcentinib will be administered once daily. On first 3 days of administration the dose will be a loading of 400mg. From Day 4 onwards, patients will receive a daily dose of 200mg. Each cycle will be 21 days. Pembrolizumab will be given at a fixed dose of 200mg via IV infusion on Day 1 of each 21-day cycle. Each drug will be administered for up to 35 cycles or until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression. Injection, Capsule. Intravenous use, Oral use.
    id
    FG002
    title
    MiST-3
  4. description
    Atezolizumab and Bevacizumab in relapsed mesothelioma. Atezolizumab will be given as a fixed dose of 1200mg via IV infusion on day 1 of a 21-day cycle. Bevacizumab will be given as 15 mg/kg via IV infusion on Days 1 of a 21-day cycle. Infusion. Intravenous use.
    id
    FG003
    title
    MiST-4
  5. description
    Dostarlimab and Niraparib in Patients with Platinum Sensitive Relapsed Mesothelioma. Niraparib will be administered once daily depending on patient's weight and platelet count. A cycle consist of 21 days and there will be up to 35 cycles in total: • ≥77 kg and ≥150,000 μL 300 mg (3 X 100 mg capsules) • \<77 kg or \<150,000 μL 200 mg (2 X 100 mg capsules) Dostarlimab will be given at a fixed dose of 500mg via IV infusion on Day 1 of each 21-day cycle for 4 cycles. Followed by 1000mg via IV infusion on Day 1 of each 42-day cycle for up to 24 months. • Each will be administered for up to 24 months or until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression. Capsule, Infusion. Oral use, Intravenous use.
    id
    FG004
    title
    MiST-5
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      2. group Id
        FG001
        num Subjects
        26
      3. group Id
        FG002
        num Subjects
        26
      4. group Id
        FG003
        num Subjects
        26
      5. group Id
        FG004
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        26
      2. group Id
        FG001
        num Subjects
        26
      3. group Id
        FG002
        num Subjects
        26
      4. group Id
        FG003
        num Subjects
        26
      5. group Id
        FG004
        num Subjects
        26
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Baseline
  2. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Physician Decision
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        3
      5. group Id
        FG004
        num Subjects
        0
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        6
      3. group Id
        FG002
        num Subjects
        4
      4. group Id
        FG003
        num Subjects
        5
      5. group Id
        FG004
        num Subjects
        5
      type
      Lack of Efficacy
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Toxicity
    5. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Patient Choice
    6. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Did not attend 12 week CT scan
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      2. group Id
        FG001
        num Subjects
        26
      3. group Id
        FG002
        num Subjects
        26
      4. group Id
        FG003
        num Subjects
        26
      5. group Id
        FG004
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        18
      2. group Id
        FG001
        num Subjects
        14
      3. group Id
        FG002
        num Subjects
        18
      4. group Id
        FG003
        num Subjects
        18
      5. group Id
        FG004
        num Subjects
        21
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        12
      3. group Id
        FG002
        num Subjects
        8
      4. group Id
        FG003
        num Subjects
        8
      5. group Id
        FG004
        num Subjects
        5
      type
      NOT COMPLETED
    title
    12 Weeks
  3. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        1
      type
      Physician Decision
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Missed 24 week visit
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        4
      4. group Id
        FG003
        num Subjects
        1
      5. group Id
        FG004
        num Subjects
        3
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      type
      Patient Choice
    5. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        4
      4. group Id
        FG003
        num Subjects
        8
      5. group Id
        FG004
        num Subjects
        6
      type
      Lack of Efficacy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        18
      2. group Id
        FG001
        num Subjects
        14
      3. group Id
        FG002
        num Subjects
        18
      4. group Id
        FG003
        num Subjects
        18
      5. group Id
        FG004
        num Subjects
        21
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        10
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        10
      4. group Id
        FG003
        num Subjects
        9
      5. group Id
        FG004
        num Subjects
        11
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        8
      4. group Id
        FG003
        num Subjects
        9
      5. group Id
        FG004
        num Subjects
        10
      type
      NOT COMPLETED
    title
    24 Weeks
pre Assignment Details
The MiST Master protocol states "Trial Design of the MiST study is in three stages: Stage 1-molecular pre-screening: The MiST Master protocol describes the identification of patients, biomarker testing and analysis. Stage 2- Treatment: The MiST treatment protocol will be specific to the treatment allocated to the patient Stage 3-Genomic Profiling": The Screening target for the pre-screening stage was 186 patients. After screening the number recruited for the treatment stage was 130 patients.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Independent clinical review pending · Not medical advice